Apogee Announces First Participants Dosed Ahead Of Schedule In Phase 1 Trial Of APG777 For Atopic Dermatitis And Other Inflammatory Diseases; Initial Subcutaneous Pharmacokinetic, Safety Data From Healthy Volunteers Anticipated In Mid-2024
Portfolio Pulse from Benzinga Newsdesk
Apogee has announced that the first participants in its Phase 1 trial of APG777 for atopic dermatitis and other inflammatory diseases have been dosed ahead of schedule. Initial subcutaneous pharmacokinetic and safety data from healthy volunteers is expected in mid-2024.
August 07, 2023 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apogee's Phase 1 trial of APG777 is progressing ahead of schedule, which could potentially accelerate the drug's development timeline.
The news that Apogee's Phase 1 trial is ahead of schedule is directly relevant to the company and its stock. This could potentially accelerate the drug's development timeline, which would be a positive development for the company and could positively impact its stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100